Resverlogix CorpOTC Pink - Current Information:RVXCFView on Canadian Exchange
- LAST PRICE0.0467
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0438/ 180
- Ask / Lots0.0484/ 250
- Open / Previous Close--- / 0.0467
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Sep 3, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Resverlogix Corp | 18.0M | --- | --- |
Company Information
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Contact Information
- Headquarters
- 300-4820 Richard Rd SWCALGARY, AB, Canada T3E 6L1
- Phone
- 403-254-9252
- Fax
- 403-254-9252
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 276.6M |
Resverlogix Corp does not pay a dividend. | |
Beta | 0.76 |
EPS | $-0.06 |
Book Value | $-0.37 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
